GSK lower after FDA briefing documents for myeloma drug

Shares of GSK (GSK) moved lower after the FDA posted briefing documents ahead of its July 17 advisory panel meeting for Blenrep, an antibody-drug conjugate developed by GSK for the treatment of multiple myeloma. Shares of GSK are down 2% to $37.70 in late morning trading. The documents read: “Overall, the benefit-risk profile of Blenrep is strongly favorable…The safety profile is manageable, and ocular events were generally reversible when managed with dose reductions or dose delays enabling participants to continue treatment.”